Fed Governor Cook sues Trump over firing attempt
Investing.com - Mizuho (NYSE:MFG) raised its price target on Neurocrine Bio. (NASDAQ:NBIX) to $145.00 from $140.00 on Thursday, while maintaining a Neutral rating on the stock. The biotech company, currently valued at $13.1 billion, has demonstrated strong revenue growth of 21.7% over the last twelve months.
The price target increase follows Neurocrine’s second-quarter 2025 results, which Mizuho described as "solid." The company’s Ingrezza medication performed slightly ahead of sell-side expectations, while Crenessity outperformed both sell-side and buy-side targets. According to InvestingPro data, the company maintains a "GREAT" financial health score, with liquid assets exceeding short-term obligations.
Despite these positive results, Neurocrine lowered its 2025 Ingrezza guidance by $25 million at the midpoint, which Mizuho suggested might explain "modest weakness" in the stock as some investors had expected stronger Ingrezza performance.
Mizuho maintained its 2025 Ingrezza sales forecast, which aligns with the midpoint of Neurocrine’s new guidance. The firm significantly increased its 2025 sales forecast for Crenessity from $91 million to $223 million, citing "better-than-expected and strong adoption trends" with 664 new patient start forms in the second quarter.
The firm’s Neutral rating remains unchanged, with Mizuho citing valuation as the primary factor for maintaining this position.
In other recent news, Neurocrine Biosciences reported impressive financial results for the second quarter of 2025, significantly exceeding analysts’ expectations. The company achieved earnings per share of $1.65, which was a notable increase over the projected $0.96, marking a surprise of 71.88%. Revenue also surpassed forecasts, reaching $687.5 million compared to the anticipated $653.32 million, a 5.23% increase. Additionally, BMO Capital raised its price target for Neurocrine Biosciences to $124 from $115, while maintaining a Market Perform rating. This adjustment reflects higher projected revenues for Crenessity, following a strong launch that exceeded consensus expectations by 122%. These developments highlight the company’s recent successes and positive performance in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.